Global Increase In ADHD Diagnoses Due To Drug Company Marketing And Lobbying, Study Shows | The Galactic Free Press

Like many other so-called “behavioral” disorders, attention deficit hyperactivity disorder, or ADHD, is a completely fabricated condition that was invented for the sole purpose of turning normal behavioral variances into “diseases” that require costly drug interventions. This crafty pharmaceutical scam is now spreading around the world, according to a new study, with drug companies effectively lobbying foreign governments to loosen their marketing restrictions on mind-altering drug treatments in order to get more people hooked on legal drugs.


ADHD diagnoses spreading from America to Europe, Ritalin prescriptions follow

It used to be that ADHD primarily existed only in the U.S., with an overwhelming 90 percent of the world’s Ritalin prescriptions being filled in the States. But this plague of intentionally drugging children with unique personality traits is now spreading to Europe and beyond as American influences progressively topple regulatory restrictions that protect the public from becoming Big Pharma victims, and replace them with policies that treat every child like a defective human in need of mind-altering drugs.

Published in the journal Social Science and Medicine, the study looked at the growth of ADHD diagnoses in places like the U.K., Germany, France, Italy, and Brazil. Together, these countries have captured at least 15 percent of Ritalin prescriptions over the past decade, reducing America’s share to 75 percent. Psychological problems that used to be treated with non-drug interventions like talk therapy are now embracing biological psychiatry – that is, forcibly changing people’s brain chemistries with pharma poisons.

“More European and South American psychologists and psychiatrists are adopting the American-based Diagnostic and Statistical Manual (DSM) standards, which are broader and have a lower threshold for diagnosing ADHD,” explains a news release summarizing the study’s findings. “Vocal ADHD advocacy groups work closely withdrug companies to promote pharmaceutical treatment.”

Sweeping diagnosis questionnaires label virtually everyone as behaviorally ‘ill’

But how do you effectively convince otherwise healthy people that they have a behavioral disease in need of drug treatments? One way is to offer online self-assessment questionnaires that are carefully designed to categorize normal behavioral differences as flawed, manipulating individuals to believe that they are sick.

When searching for health information online, web users are increasingly redirected to drug-promoting “resources” that ask generic questions like “Do you fidget a lot?” and “Is it hard for you to concentrate?” Most people would probably agree that they feel this way at least some of the time, and by ignorantly answering “yes” to these and other self-diagnosis questions, they end up being funneled into the system and signed up as new drug customers for completely made-up diseases.

“These checklists turn all kinds of different behaviors into medical problems,” explains Peter Conrad, a professor at Brandeis University and one of the study’s lead authors. “The checklists don’t distinguish what is part of the human condition and what is a disease.”

Many people don’t know that they’re being scammed when they fall into these crafty drug industry traps, and the result is that many of them end up becoming pharma addicts for life. According to the study, less than one percent of children in the U.K., for instance, were behavioral drug addicts in the early 1990s. But today, about five percent of the population is a behavioral drug user.

In Germany, the increase has been even more stark. Between 1998 and 2008, ADHD drug use soared by more than 500 percent, jumping from 10 million daily doses to roughly 53 million daily doses.

“There is no pharmacological magic bullet,” adds Conrad, noting that pharmaceutical drugs are not the answer to behavioral difference. “I think we may look back on this time in 50 years and ask, what did we do to these kids?”


ADHD Diagnoses Up 66 Percent Since 2000.

According to a new study, the number of children diagnosed with attention deficit hyperactivity disorder (ADHD) has increased by 66 percent over the past 10 years.

Researchers analyzed changes in the diagnosis of youth ADHD and treatment of the disorder from 2000 to 2010. Only youth under the age of 18, and cared for by office-based physicians, were included in the evaluation.

Northwestern University researchers also discovered that specialists, instead of primary care physicians, have begun treating an increasing number of these young patients.

Psychostimulants such as methylphenidate (Ritalin) remain the most common medication prescribed to children with ADHD. Psychostimulants were used in 96 percent of treatments in 2000 and 87 percent in 2010.

“ADHD is now a common diagnosis among children and teens,” said lead author Craig Garfield, M.D. “The magnitude and speed of this shift in one decade is likely due to an increased awareness of ADHD, which may have caused more physicians to recognize symptoms and diagnose the disorder.”

Symptoms of ADHD, such as trouble paying attention and controlling impulsive behaviors and being overly active, can affect children and teens both academically and socially, Garfield said.

In the past decade several important regulatory and clinical changes regarding ADHD and the medications used to treat it have occurred, yet it was unknown how these factors have affected ADHD management, Garfield said.

For the study, Garfield and his team of researchers quantified ADHD diagnosis and treatment patterns among people under 18 using the IMS Health National Disease and Therapeutic Index. This is a nationally representative sample of office-based visits and included 4,300 office-based physicians in 2010.

According to the study, in 2010, 10.4 million children and teens under age 18 were diagnosed with ADHD at physician outpatient visits, versus 6.2 million in 2000.

Investigators were unable to explain the reduction in use of psychostimulants during the decade studied although they did note that there was not an increase in treatment with other, substitute medications.

Although the majority of children and teens with ADHD are still managed by primary physicians, researchers determined a significant shift away from primary doctors and toward specialists, such as pediatric psychiatrists.

“Recently, there’s been more public health advisories issued about problems or side effects of different ADHD medications,” Garfield said. “It may be that general pediatricians are shying away from treating patients themselves and instead rely on their specialist colleagues to provide the treatment and management of these medications.”

Given the short supply of psychiatrists specializing in pediatric ADHD, Garfield said this trend might make it difficult for many children to receive medical treatment for ADHD in the future.

The study will be published in the March/April issue of the journal Academic Pediatrics.

Source: Northwestern University